Evaluating the Efficacy of CPAP Therapy for the Treatment of Fatty Liver
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01849081|
Recruitment Status : Withdrawn (Change in priorities, study closed prior to enrollment)
First Posted : May 8, 2013
Last Update Posted : October 6, 2020
|Condition or disease||Intervention/treatment||Phase|
|Non-alcoholic Fatty Liver Disease||Device: CPAP Behavioral: LIfestyle||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluating the Efficacy of CPAP Therapy for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)|
|Estimated Study Start Date :||March 2019|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||March 2019|
Subjects in this arm with receive treatment with CPAP for fatty liver disease.
Subjects in the intervention arm will be treated with continuous positive airway pressure (CPAP) device at night.
Active Comparator: Lifestyle Intervention
Subjects in the lifestyle arm will undergo 12 weeks of dietary counseling.
Subjects will undergo 12 weeks of dietary counseling.
- Steatosis by MRS [ Time Frame: 12 weeks ]Subjects will undergo baseline and 12 week magnetic resonance spectroscopy to assess the impact of CPAP or diet on fatty liver.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01849081
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Kathleen E Corey, MD, MPH||Massachusetts General Hospital|